New $300 Million Plant Will Make Inhaled Insulin


By: Kya Fawley

Two pharmaceutical companies recently joined forces and invested $300 million in a new plant that will produce inhaled insulin.

Hoechst Marion Roussel (HMR), part of Hoechst AG pharmaceuticals, and Pfizer have already laid the foundation for the insulin plant, located in the Hoechst industrial park in Frankfurt, Germany.

HMR and Pfizer agreed to jointly produce and market an inhaled insulin product in November 1998. Their product is now in phase three of clinical trials.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.